Onconetix logo

OnconetixNASDAQ: ONCO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

18 February 2022

Next earnings report:

20 May 2025

Last dividends:

N/A

Next dividends:

N/A
$1.05 M
-99%vs. 3y high
4%vs. sector
-vs. 3y high
-vs. sector
-100%vs. 3y high
16%vs. sector
-99%vs. 3y high
20%vs. sector

Price

after hours | Sat, 16 Nov 2024 00:24:35 GMT
$1.41-$0.26(-15.56%)

Dividend

No data over the past 3 years
$704.80 K-$14.31 M

Analysts recommendations

Institutional Ownership

ONCO Latest News

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit
globenewswire.com03 October 2024 Sentiment: POSITIVE

CINCINATTI, OH., Oct. 03, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Onconetix, Inc. (Nasdaq: ONCO), please note that in the first paragraph of the release, the name of the financial advisor to Onconetix in the transaction had been corrected to Tungsten Advisors. The corrected release follows.

Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit
globenewswire.com03 October 2024 Sentiment: POSITIVE

CINCINATTI, Oh., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or “the Company”) (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of innovative solutions for oncology, today announced the signing and closing of a private placement of (i) 3,499 shares of the Company's Series C Convertible Preferred Stock, $0.00001 par value (the “Series C Preferred Stock”), and (ii) warrants (the “Warrants”) to acquire up to an aggregate of 591,856 additional shares of the Company's common stock, $0.00001 par value per share (the “Common Stock”), for aggregate gross proceeds of approximately $2.0 million. The Series C Preferred Stock are initially convertible into an aggregate of 776,590 shares of Common Stock, subject to certain anti-dilution adjustments. The Warrants will have an exercise price of $4.38 per share, subject to customary adjustments, and are exercisable beginning six months and one day after the issuance date (the “Initial Exercisability Date”) and expiring on the third anniversary of the Initial Exercisability Date. The Company has filed a Current Report on Form 8-K with the Securities and Exchange Commission on October 3, 2024, with additional details of the transaction. The Company agreed to seek stockholder approval for the issuance of all of the shares of Common Stock issuable upon conversion of the Series C Preferred Stock and exercise of the Warrants in accordance with the rules and regulations of the Nasdaq Stock Market. The Company intends to use the gross proceeds from the private placement for working capital and general corporate purposes. Tungsten Advisors (through its broker-dealer, Finalis Securities, LLC), served as financial advisor to Onconetix. Additionally, on October 2, 2024, Onconetix entered into a Common Stock Purchase Agreement with an equity line institutional investor (the “Purchaser”), whereby the Company has the right, but not the obligation, to sell to the Purchaser, and, subject to limited exceptions, the Purchaser is obligated to purchase, up to $25 million of newly issued shares of the Company's common stock. The Company's right to commence sales of Common Stock to the Purchaser are subject to certain conditions, including that a registration statement covering the resale of such shares is declared effective by the SEC. Actual sales of shares of Common Stock to the Purchaser under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the Common Stock and determinations by the Company as to the appropriate sources of funding and the Company's operations. “We are pleased to announce this private placement and the equity line of credit,” said Ralph Schiess, Interim CEO. “The Company expects to use the proceeds from the financing to fund operations and potential growth opportunities."

Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders
globenewswire.com20 September 2024 Sentiment: NEUTRAL

CINCINNATI, Ohio, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today announced that the Company's stockholders have approved all proposals voted on at the Company's 2024 annual meeting of stockholders (the “Annual Meeting”) held on September 5, 2024, and that its Board of Directors (the “Board of Directors” or “Board”) approved a 1-for-40 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on Tuesday, September 24, 2024.

Why Is Onconetix (ONCO) Stock Up 37% Today?
investorplace.com18 July 2024 Sentiment: POSITIVE

Onconetix (NASDAQ: ONCO ) stock is taking off on Thursday alongside heavy pre-market trading of the biotechnology company's shares. This has more than 38 million shares of ONCO stock changing hands as of this writing.

Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds
globenewswire.com15 July 2024 Sentiment: POSITIVE

CINCINNATI, July 15, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (“Onconetix” or the “Company”) (Nasdaq: ONCO), today announced the closing of the previously announced exercise of certain existing warrants to purchase 7,458,642 shares of its common stock having exercise prices ranging from $1.09 to $2.546 per share, at a reduced exercise price of $0.15 per share. The aggregate gross proceeds from the exercise of the existing warrants were approximately $1.11 million, before deducting placement agent fees and other offering expenses payable by the Company.

Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds
globenewswire.com11 July 2024 Sentiment: POSITIVE

CINCINNATI, Ohio, July 11, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (“Onconetix” or the “Company”) (Nasdaq: ONCO), today announced it has entered into definitive agreements for the immediate exercise of certain existing warrants to purchase 7,458,642 shares of its common stock originally issued in August 2022 and August 2023, having exercise prices ranging from $1.09 to $2.546 per share, at a reduced exercise price of $0.15 per share. The transaction is expected to close on or about July 12, 2024, subject to satisfaction of customary closing conditions.

What type of business is Onconetix?

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

What sector is Onconetix in?

Onconetix is in the Healthcare sector

What industry is Onconetix in?

Onconetix is in the Biotechnology industry

What country is Onconetix from?

Onconetix is headquartered in United States

When did Onconetix go public?

Onconetix initial public offering (IPO) was on 18 February 2022

What is Onconetix website?

https://onconetix.gcs-web.com

Is Onconetix in the S&P 500?

No, Onconetix is not included in the S&P 500 index

Is Onconetix in the NASDAQ 100?

No, Onconetix is not included in the NASDAQ 100 index

Is Onconetix in the Dow Jones?

No, Onconetix is not included in the Dow Jones index

When was Onconetix the previous earnings report?

No data

When does Onconetix earnings report?

The next expected earnings date for Onconetix is 20 May 2025